rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ERNA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
      Oct 22Yahoo FinanceERNA
      Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

      Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET Register here CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today a

      Oct 12Yahoo FinanceERNA
      Ernexa presents preclinical data on ERNA-101 at MD Anderson
      Oct 6Investing.comERNA
      Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

      Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in HoustonCAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a

      Oct 6Yahoo FinanceERNA
      Ernexa appoints Robert Spiegel to board, targets IND filing
      Oct 1Investing.comERNA
      Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
      Oct 1Yahoo FinanceERNA
      Ernexa completes safety studies for ERNA-101 cancer therapy
      Sep 30Investing.comERNA
      Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
      Sep 30Yahoo FinanceERNA
      Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
      Sep 29Yahoo FinanceERNA
      Eterna Therapeutics appoints independent director Robert J. Spiegel

      Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailERNA
      Ernexa appoints Robert Spiegel to board of directors
      Sep 17Investing.comERNA
      Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

      Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the

      Sep 17Yahoo FinanceERNA
      Ernexa reports preclinical data for ERNA-201, refocuses on oncology
      Sep 15Investing.comERNA
      Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment

      Sep 14Yahoo FinanceERNA
      Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

      Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes

      Aug 27Yahoo FinanceERNA

      This is the newest page. Registered accounts read further back.